HENLIUS (02696) released its annual performance, with revenue of 6.67 billion yuan, a year-on-year increase of 16.46%.

HENLIUS (02696) announced its annual performance as of December 31, 2025. The group generated revenue of 6.67 billion yuan, an increase of 16.46% year-on-year; the profit attributable to owners of the parent company was 827 million yuan, an increase of 0.8% year-on-year; the basic earnings per share were 1.52 yuan. As of the end of the year on December 31, 2025, the group confirmed R&D expenditure of approximately 2.492 billion yuan, an increase of approximately 651 million yuan compared to the previous year, mainly used to increase investment in innovative R&D projects to accelerate the group's innovation transformation. Among them, R&D expenditure recognized as expenses was approximately 1.515 billion yuan, an increase of approximately 480 million yuan compared to the previous year. As of the end of the year on December 31, 2025, the group's total profit was approximately 827 million yuan, an increase of approximately 6.5 million yuan compared to the previous year, mainly due to the continued increase in sales volume of core products, significant growth in overseas commercialization profits, and expansion of R&D clinical activities. Among them, profits from overseas products (including overseas product supply gross margin and profits based on sales of franchise rights) were approximately 93.9 million yuan.